Modifiable Variables in Parkinsonism Study

Overview

Overview

This observational study investigates modifiable lifestyle and environmental factors that may influence the risk, progression, and severity of [Parkinson's disease](/diseases/parkinsons-disease) and related disorders, including [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), [Multiple System Atrophy](/diseases/multiple-system-atrophy), and [Corticobasal Degeneration](/diseases/corticobasal-degeneration)[@kalia_2015].

While genetic factors contribute to Parkinson's disease risk, the majority of cases are sporadic, suggesting that environmental and lifestyle factors play a significant role["@noyce_2012"]. This study aims to characterize these modifiable factors to identify potential prevention strategies and disease-modifying interventions["@foltynie_2021"].

[Parkinson's disease](/diseases/parkinsons-disease) affects approximately 1-2% of the population over 65 years, rising to 3-5% in those over 85[@jankovic_2020]. The global prevalence is estimated at over 10 million people. Key epidemiological features include:

• Slight male predominance (1.5:1 ratio)
• Typical onset between 50-70 years
• Increasing incidence with age
• Geographic variation in prevalence

Study Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT02194816 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP, MSA, CBS |
| Sites | United States (multiple centers) |
| Enrollment | Target: Multiple participants |
| Start Date | 2014 |

Risk Factors Overview

Multiple factors influence Parkinson's disease risk[@bellou_2016]:

Non-Modifiable Factors

• Age (strongest risk factor)
• Male sex
• Genetic susceptibility (family history, specific genes)
• Ethnic background

Potentially Modifiable Factors

• Pesticide exposure
• Head trauma
• Dairy product consumption
• Psychological stress

Potentially Protective Factors

• Caffeine consumption
• Physical activity
• Smoking (controversial - nicotine vs. confounding)
• Alcohol consumption (moderate)
• Anti-inflammatory drug use

Study Objectives

Primary Objectives

• Document caffeine and nicotine use
• Assess physical activity levels
• Evaluate dietary patterns
• Record medication history

• Occupational history
• Pesticide exposure assessment
• Living environment
• Water source

• Disease severity measures
• Progression rates
• Motor and non-motor symptoms
• Treatment response

• Risk factor quantification
• Protective factor validation
• Target population identification

Secondary Objectives

• Evaluate gender-specific effects
• Assess age-of-onset relationships
• Characterize gene-environment interactions
• Develop risk prediction models

Assessment Areas

Caffeine and Nicotine Use

Epidemiological studies consistently show inverse associations between caffeine consumption and Parkinson's disease risk[@hernandez_2019]:

• Coffee consumption: 30-60% risk reduction in meta-analyses
• Tea consumption: similar inverse association
• Caffeine dose-response relationship
• Potential neuroprotective mechanisms:
• Adenosine A2A receptor antagonism
• Antioxidant effects
• Anti-inflammatory properties

• Historical smoking association with reduced PD risk
• Contributes to inverse association in some studies
• Confounded by lifestyle factors
• Nicotinic receptor modulation as therapeutic target

Physical Activity

Exercise and physical activity have emerged as potentially disease-modifying interventions[@chen_2019]:

• Regular exercise associated with 30-50% risk reduction
• Mechanisms include:
• Neurotrophic factor upregulation
• Mitochondrial function improvement
• Neuroinflammation reduction
• Alpha-synuclein clearance enhancement
• Recommended exercise types:
• Aerobic exercise
• Balance training
• Resistance training
• Dance-based therapies

Dietary Patterns

Nutritional factors influence Parkinson's disease risk[@gao_2011]:

• Potentially Protective:
• Mediterranean diet
• Omega-3 fatty acids
• Fruits and vegetables
• Antioxidant-rich foods
• Potentially Risk-Increasing:
• High dairy intake
• Saturated fats
• Processed foods
• Mediterranean Diet Evidence[@delenord_2019]:
• Associated with lower PD risk
• Benefits from anti-inflammatory effects
• Rich in polyphenols and antioxidants

Medication History

Certain medications may modify Parkinson's disease risk:

• Statins: Conflicting evidence - some studies show reduced risk[@logroscino_2018]
• NSAIDs: Mixed results for anti-inflammatory effects
• Beta-blockers: Theoretical benefits via adrenergic modulation
• Calcium channel blockers: Some protective signals

Occupational Exposures

Pesticide and chemical exposures represent significant risk factors[@ascherio_2016]:

Pesticide Exposure

• Herbicides: Paraquat, rotenone
• Insecticides: Organophosphates, pyrethroids
• Fungicides: Maneb, mancozeb

• Mitochondrial complex I inhibition
• Oxidative stress induction
• Alpha-synuclein aggregation promotion
• Dopaminergic neuron selectivity

Occupations at Risk

• Agricultural workers
• Pesticide applicators
• Farm managers
• Greenhouse workers

• Personal protective equipment
• Engineering controls
• Safe handling practices
• Rotation of duties

Clinical Measures

Movement Disorder Assessments

MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)

The gold-standard assessment tool:

• Part I: Non-motor experiences of daily living
• Part II: Motor experiences of daily living
• Part III: Motor examination
• Part IV: Motor complications

Hoehn and Yahr Staging

• Stage 0: No signs of disease
• Stage 1: Unilateral involvement
• Stage 1.5: Unilateral and axial involvement
• Stage 2: Bilateral involvement without impairment
• Stage 2.5: Mild bilateral disease with recovery on pull test
• Stage 3: Mild to moderate disease, some postural instability
• Stage 4: Severe disability, still able to walk/stand
• Stage 5: Wheelchair-bound or bedridden

PSP Rating Scale (PSPRS)

For PSP and related disorders:

• Gait and mobility
• Ocular motor dysfunction
• Dysphagia
• Cortical dysfunction
• Axonal rigidity

Non-Motor Assessments

Cognitive Testing

• Montreal Cognitive Assessment (MoCA)
• Trail Making Test
• Word fluency
• Memory recall

Psychiatric Evaluation

• Beck Depression Inventory
• State-Trait Anxiety Inventory
• apathy assessment

Sleep Assessment

• REM sleep behavior disorder questionnaire
• Epworth Sleepiness Scale
• Polysomnography when indicated

Quality of Life Measures

• Parkinson's Disease Questionnaire-39 (PDQ-39)
• SF-36 Health Survey
• Caregiver burden scales

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of Parkinson's disease, PSP, MSA, or CBS
• UK Brain Bank criteria or equivalent
• Progressive disease course

• Age 40-90 years
• Disease duration any stage

• Able to complete questionnaires
• Available for study visits
• Informed consent obtained

Exclusion Criteria

• Drug-induced parkinsonism
• Vascular parkinsonism
• Normal pressure hydrocephalus

• Unable to complete study procedures
• Terminal illness
• Severe cognitive impairment preventing consent

Study Design

Cross-Sectional Components

• Baseline lifestyle questionnaire
• Environmental exposure assessment
• Clinical phenotype characterization

Longitudinal Components

• Annual follow-up assessments
• Disease progression tracking
• Change in exposure status documentation

Data Collection Methods

• Interviewer-administered questionnaires
• Self-administered diaries
• Medical record review
• Biological sample collection

Understanding Disease Mechanisms

This study contributes to understanding how environmental factors influence neurodegenerative processes:

• How genetic susceptibility modifies environmental risk
• Epigenetic modifications from exposures

• Identification of environmental triggers
• Understanding of protective mechanisms

Prevention Strategies

Identifying modifiable risk factors enables development of prevention strategies[@kieburtz_2019]:

• Reducing pesticide exposure
• Promoting physical activity
• Dietary modifications

• Early identification of prodromal markers
• Intervention before significant neurodegeneration

• Targeting mechanisms influenced by lifestyle
• Complementing pharmacological approaches

Clinical Trial Implications

• Risk Factor Modification: Lifestyle interventions as adjuncts to pharmacological treatments
• Endpoint Selection: Environmental factors affecting progression
• Patient Stratification: Exposure-based phenotyping
• Neuroprotective Trials: Environmental modifiers as targets

Limitations and Challenges

Observational Design

• Cannot establish causality
• Potential for confounding
• Recall bias in exposure assessment

Exposure Assessment

• Latency between exposure and disease
• Difficulty quantifying exposures
• Recall limitations

Generalizability

• Geographic specificity
• Referral bias
• Cohort representativeness

Related Mechanisms and Pathways

Parkinson's Disease Pathogenesis

• [Alpha-synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Oxidative Stress](/mechanisms/oxidative-stress)

Protective Mechanisms

• [Exercise-Induced Neuroprotection](/mechanisms/exercise-neuroprotection)
• [Caffeine Neuroprotection](/mechanisms/caffeine-neuroprotection)
• [Antioxidant Defense](/mechanisms/antioxidant-defense)

Risk Factors

• [Pesticide-Induced Neurodegeneration](/mechanisms/pesticide-neurotoxicity)
• [Traumatic Brain Injury](/mechanisms/tbi-neurodegeneration)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Environmental Risk Factors](/mechanisms/environmental-risk-factors)
• [Lifestyle and Neurodegeneration](/mechanisms/lifestyle-neurodegeneration)

External Links

• [ClinicalTrials.gov NCT02194816](https://clinicaltrials.gov/study/NCT02194816)
• [Michael J. Fox Foundation](https://www.michaeljfox.org)
• [Parkinson's Foundation](https://www.parkinson.org)

References